Alogliptin – a new DPP-4 inhibitor for type 2 diabetes

Alogliptin (Vipidia), the latest DPP-4 inhibitor, is licensed as second-line therapy in patients with type 2 diabetes mellitus. Steve Chaplin presents the data relating to its efficacy and adverse events and Azhar Farooqi outlines its place in therapy.

Alogliptin a new DPP 4 inhibitor for type 2 diabetes

Add yours ↓
Web design and marketing agency Leamington Spa